This HTML5 document contains 146 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n13http://dx.doi.org/10.1038/
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
n8https://scigraph.springernature.com/pub.10.1038/
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q36467826
rdf:type
wikibase:Item
schema:description
научни чланак article scientifique (publié 1989) scienca artikolo articolo scientifico artigo científico 1989年學術文章 mokslinis straipsnis επιστημονικό άρθρο مقالة علمية نشرت في ديسمبر 1989 article scientific naučni članak 1989年學術文章 artículo científico publicado en 1989 tudományos cikk научни чланак 1989 nî lūn-bûn vedecký článok artigo científico (publicado na 1989) article científic 1989年学术文章 ১৯৮৯-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 1989年の論文 bài báo khoa học scientific article artículu científicu espublizáu en 1989 научная статья 1989年學術文章 wissenschaftlicher Artikel teaduslik artikkel мақолаи илмӣ سائنسی مضمون գիտական հոդված บทความทางวิทยาศาสตร์ articol științific artikulong pang-agham מאמר מדעי 1989年学术文章 1989年學術文章 wetenschappelijk artikel bilimsel makale vitskapeleg artikkel artigo científico (publicado na 1989) 1989年学术文章 videnskabelig artikel (udgivet 1989) научна статия vetenskaplig artikel vědecký článek 1989年学术文章 1989年學術文章 мақолаи илмӣ სამეცნიერო სტატია наукова стаття, опублікована в грудні 1989 1989년 논문 مقالهٔ علمی artikull shkencor tieteellinen artikkeli artykuł naukowy 1989年学术文章 vitenskapelig artikkel 1989年學術文章
p:P577
wds:Q36467826-8F4E5377-1342-4044-9A16-7D6834C9E331
wdt:P577
1989-12-01T00:00:00Z
p:P407
wds:Q36467826-D14E215B-0CBE-4353-9FDB-EE9BFF66BD4E
wdt:P407
wd:Q1860
p:P2888
wds:Q36467826-02367CB8-B5EE-4CDA-B595-4FFD37E108A0
wdt:P2888
n8:bjc.1989.392
p:P2860
wds:Q36467826-873CF151-EC3D-4465-AEF0-5F2E17FE9E3B wds:Q36467826-98136616-29B5-436F-8A51-BD54CC9565BC wds:Q36467826-9955896E-3FE6-4686-A1BC-1B8ADCF6DEE8 wds:Q36467826-A01783D8-D01B-4A48-8F77-4C11EE02649B wds:Q36467826-A5F677DC-7DA8-4D96-9F35-AD47724139E9 wds:Q36467826-BBB48353-303B-4886-8634-B053707DE78C wds:Q36467826-E2B1AE31-DFEB-40A8-B4F6-9F3CF55C168F wds:Q36467826-1A7BE8BC-2052-451A-B24E-BE9B7C5EF703 wds:Q36467826-5BBFDF7C-BCD7-4317-BC1D-5CD89793AFEA wds:Q36467826-66E1D69F-515E-4712-B9EB-52D3B4902417 wds:Q36467826-715EF01E-31A6-4527-9998-C96B79073C3D wds:Q36467826-F262DA28-D618-49D3-B508-D444ADDD224C
wdt:P2860
wd:Q35992425 wd:Q38184652 wd:Q71174983 wd:Q41811600 wd:Q70092222 wd:Q52072984 wd:Q58236593 wd:Q40125596 wd:Q46083133 wd:Q70142553 wd:Q51230896 wd:Q53942854
p:P2093
wds:Q36467826-0350C9F1-8FC4-43C0-99E5-492BFCCBDEDF wds:Q36467826-38C06685-047E-4DE8-9271-F9BCDD524AD8 wds:Q36467826-274943D0-C202-4281-BE81-B5E57D945134 wds:Q36467826-218D424A-573D-4A4C-8D65-D6A87BE46392 wds:Q36467826-68353966-169C-4AD2-9767-83C335DE62A8 wds:Q36467826-518B7DAD-F764-42DE-BCF3-5EC2D728F2C6 wds:Q36467826-CEE45C40-A234-47E1-BED3-8E1BEEF00644 wds:Q36467826-CFD6E619-F335-4A58-9D89-E26B4673EED7 wds:Q36467826-BCA3BDC5-442D-440B-BEDC-11084B2D110E wds:Q36467826-BBA27DC8-05E6-4097-96D6-443024A69957
wdt:P2093
Arnold M Wu PC Chung HT Lau JY Lin HJ Yeoh EK Lai CL Ngan H Ng MM Lok AS
rdfs:label
Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial
skos:prefLabel
Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial
schema:name
Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial
p:P1476
wds:Q36467826-352E7CE7-1E8B-4271-81B9-FBB6D9EBF151
wdt:P1476
Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial
p:P304
wds:Q36467826-8B1386C8-4505-4561-ACB3-F740344110F3
wdt:P304
928-933
p:P31
wds:Q36467826-5B04FEF3-F3C3-48A6-9007-1FFB3E8D68F5
wdt:P31
wd:Q13442814
p:P921
wds:Q36467826-BFDE1308-C34C-4B05-B4D6-EE7149300C34 wds:Q36467826-51FC6F25-7A1C-47E1-9D27-EC7C712FE250
wdt:P921
wd:Q18936 wd:Q1148337
p:P698
wds:Q36467826-380DB408-E11D-4E9C-88E0-B6B182FCDC2A
wdtn:P698
n12:2557881
wdt:P698
2557881
p:P1433
wds:Q36467826-0357E5C6-B76B-46FD-A1E3-2EA33282AC35
wdt:P1433
wd:Q326309
p:P433
wds:Q36467826-07060131-5E18-49E5-9052-2E546F3B83A9
p:P478
wds:Q36467826-A562648D-98E9-4435-A5C5-3DC2655073EA
wdt:P433
6
wdt:P478
60
p:P356
wds:Q36467826-275DCDBA-8784-455F-9907-D75BB7325FF6
wdtn:P356
n13:BJC.1989.392
wdt:P356
10.1038/BJC.1989.392
p:P5875
wds:Q36467826-43D90865-588D-4FC7-87B2-BCD1FD363731
wdt:P5875
20598034
p:P932
wds:Q36467826-579C8149-A0FE-473F-859A-5DA80C993CAE
wdt:P932
2247256